Paul Robach, Stefania Recalcati, Domenico Girelli, Cecilia Gelfi, Niels J Aachmann-Andersen, Jonas J Thomsen, Anne M Norgaard, Alessandra Alberghini, Natascia Campostrini, Annalisa Castagna, Agnese Viganò, Paolo Santambrogio, Tibor Kempf, Kai C Wollert, Stéphane Moutereau, Carsten Lundby, Gaetano Cairo
Journal: Blood 2009;113(26):6707-15
PMID: 19264680
The high iron demand associated with enhanced erythropoiesis during high-altitude hypoxia leads to skeletal muscle iron mobilization and decrease in myoglobin protein levels. To investigate the effect of enhanced erythropoiesis on systemic and muscle iron metabolism under nonhypoxic conditions, 8 healthy volunteers were treated with recombinant erythropoietin (rhEpo) for 1 month. As expected, the treatment efficiently increased erythropoiesis and stimulated bone marrow iron use. It was also associated with a prompt and considerable decrease in urinary hepcidin and a slight transient increase in GDF-15. The increased iron use and reduced hepcidin levels suggested increased iron mobilization, but the treatment was associated with increased muscle iron and L ferritin levels. The muscle expression of transferrin receptor and ferroportin was up-regulated by rhEpo administration, whereas no appreciable change in myoglobin levels was observed, which suggests unaltered muscle oxygen homeostasis. In conclusion, under rhEpo stimulation, the changes in the expression of muscle iron proteins indicate the occurrence of skeletal muscle iron accumulation despite the remarkable hepcidin suppression that may be mediated by several factors, such as rhEpo or decreased transferrin saturation or both.
Full Text Sources:
Medical:
Research Materials:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
NED wishes to thank the following organisations for their support:
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.